Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-25-001311
Filing Date
2025-05-15
Accepted
2025-05-15 13:20:54
Documents
86
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ento-20250331x10q.htm   iXBRL 10-Q 1546460
2 EX-31.1 ento-20250331xex31d1.htm EX-31.1 11835
3 EX-31.2 ento-20250331xex31d2.htm EX-31.2 11961
4 EX-32.1 ento-20250331xex32d1.htm EX-32.1 7503
  Complete submission text file 0001410578-25-001311.txt   8625082

Data Files

Seq Description Document Type Size
5 EX-101.SCH ento-20250331.xsd EX-101.SCH 74243
6 EX-101.CAL ento-20250331_cal.xml EX-101.CAL 56237
7 EX-101.DEF ento-20250331_def.xml EX-101.DEF 324019
8 EX-101.LAB ento-20250331_lab.xml EX-101.LAB 668441
9 EX-101.PRE ento-20250331_pre.xml EX-101.PRE 493991
89 EXTRACTED XBRL INSTANCE DOCUMENT ento-20250331x10q_htm.xml XML 1370060
Mailing Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431
Business Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431 561-589-7020
Entero Therapeutics, Inc. (Filer) CIK: 0001604191 (see all company filings)

EIN.: 464993860 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37853 | Film No.: 25951009
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)